Chaga mushroom: the oxalate kidney risk the wellness market ignores

← Back to articles

Chaga (Inonotus obliquus) has become a fixture of immune and anti-aging supplement lines, marketed for everything from cancer prevention to "cellular longevity." What the marketing leaves out is that the published medical literature on chaga in humans is dominated not by efficacy trials but by case reports of acute and chronic kidney injury — including patients who reached end-stage renal disease and required dialysis. The mechanism is not exotic: chaga is one of the most oxalate-rich substances people deliberately consume, and oxalate nephropathy is a known, sometimes irreversible, kidney disease.

What chaga actually contains

Chaga is a parasitic fungus that grows on birch and other trees in cold climates. The black, woody sclerotium harvested for supplements contains beta-glucans, polyphenols, melanin pigments, betulin and betulinic acid derivatives, and a very high concentration of oxalate. Oxalate is a small organic acid that binds calcium and, when it crystallizes in the renal tubules as calcium oxalate, can mechanically injure the kidney. The oxalate load of chaga is not a theoretical concern: when Korean nephrologists chemically analyzed the chaga powder consumed by a patient who developed end-stage renal disease, it contained roughly 14.2 g of oxalate per 100 g of product — extraordinarily high for any ingested material [2].

Oxalate nephropathy: the documented harms

The clearest published harms come from biopsy-confirmed case reports. In a 2022 report in Medicine, a 69-year-old man who had taken 10–15 g of chaga powder daily alongside 500 mg of vitamin C for about three months developed acute kidney injury; renal biopsy showed acute tubular injury with calcium oxalate crystal deposition, and he required hemodialysis and high-dose steroids before recovering [1]. In a 2020 report in the Journal of Korean Medical Science, a 49-year-old man who had taken chaga powder for years to manage intractable atopic dermatitis presented with end-stage renal disease; his biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits, and his estimated daily oxalate intake was several times that of a normal diet [2]. A 2026 controlled rat study from the same group reinforced biological plausibility: high-dose chaga produced oxalate crystal deposition, tubular injury, proteinuria, and oxidative-stress markers in kidney tissue, while a lower dose did not [3]. The pattern across reports — crystals on biopsy, dose dependence, partial or no recovery — is consistent.

Who is at elevated risk

Risk is not uniform. People with pre-existing chronic kidney disease, diabetes, hypertension, dehydration, or a history of calcium oxalate kidney stones are most vulnerable, because their kidneys are less able to clear an oxalate load. Concurrent high-dose vitamin C compounds the danger, since ascorbate is metabolized in part to oxalate — the 2022 case combined chaga with 500 mg of vitamin C daily [1]. The older population that chaga marketing often targets (for "immune resilience" or cancer worry) overlaps heavily with these risk factors. Pregnancy is a relative contraindication given the physiological hyperfiltration of pregnancy.

What the efficacy data actually show

Set against these documented harms is a near-total absence of human efficacy data. The anti-cancer, anti-inflammatory, and antioxidant claims rest on cell-culture and rodent experiments with isolated polysaccharide or triterpenoid fractions, not on controlled trials in people. There is no published randomized controlled trial demonstrating that chaga supplementation prevents disease, boosts immunity, or extends healthspan in humans. So the honest risk-benefit summary is lopsided: a real, biopsy-confirmed mechanism of serious kidney injury on one side, and unproven benefit on the other.

Drug interactions and other cautions

Beyond the oxalate problem, chaga has reported mild anticoagulant and blood-glucose-lowering activity in laboratory models, raising theoretical concerns for people on warfarin or antidiabetic medication, though human interaction data are thin. These are secondary to the kidney risk, which is the dominant safety signal and the one clinicians have actually documented.

Bottom line on dosing

There is no established safe dose of chaga, because the human evidence base consists of harm reports rather than dose-finding studies. The documented injuries occurred at sustained intakes in the range of several grams to 10–15 g per day over months [1][2], so lower, occasional use with good hydration and intact kidney function is plausibly lower-risk — but "lower-risk" is not "proven safe." Anyone with a kidney risk factor should avoid chaga entirely, and anyone taking it should not pair it with high-dose vitamin C.

Sources

1. Kwon O, Kim Y, Paek JH, Park WY, Han S, Sin H, Jin K. "Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report." Medicine (Baltimore), 2022;101(10):e28997. PMID 35451393. DOI: 10.1097/MD.0000000000028997.
2. Lee S, Lee HY, Park Y, Ko EJ, Ban TH, Chung BH, Lee HS, Yang CW. "Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature." J Korean Med Sci, 2020;35(19):e122. PMID 32419395. DOI: 10.3346/jkms.2020.35.e122.
3. Lee S, Cui S, Fang X, Lee H, Lim SW, Shin YJ, Li C, Yang CW, Chung BH. "Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model." J Korean Med Sci, 2026;41(3):e37. PMID 41555803. DOI: 10.3346/jkms.2026.41.e37.